Releases

Medable announces results from a new research project with Duke University BASE Lab on enhanced electronic informed consent (eIC) in clinical trials.

‍

Medable CEO and Co-Founder Michelle Longmire will be presenting a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.

Medable was awarded ‘Best Digital Health Solution’ from a field of 24 nominees at the Prix Galien USA Forum in New York City. This recognition underscores the impact of Medable’s evidence generation platform on clinical research worldwide.

This strategic partnership combines best-in-class patient care coordination service and clinical trialsplatform to streamline execution, improve data quality, and enhance patient experience.

‍

Medable, the leading technology provider for patient-centric clinical trials, today announced that it ranked in the top 8 percent (#398) and was one of the top 50 software companies on the 2023 Inc. 5000, its annual list of the fastest-growing private companies in America. Medable’s ranking was fueled by its strong three-year growth rate of 1,453% from 2019 through 2022.

‍

MRCT Center and Medable launch  first-of-its-kind toolkit to provide a common framework, tools, and best practices for uniform ethical review and approval to simplify, streamline, and speed the IRB/EC process – a key step towards more efficient, patient-centered research execution.

‍

Steve Jones, Medable’s vice president of data analytics, achieved the silver award in the Decentralized Solutions Individual of the Year category at PharmaTimes International Clinical Researcher of the Year awards gala in London on May 18, 2023.

‍

Medable's decentralized clinical trial (DCT) platform was selected by the Nova Scotia Health Innovation Hub to increase the accessibility of oncology care for remote patients in rural Nova Scotia, with the long-term aim to improve patient access and trial diversity across Canada.

Medable, the industry-leading technology platform for patient-centered clinical trials, today announced a partnership with non-profit Every Cure, which officially launched in September in partnership with the Clinton Global Initiative to scale up an innovative “drug repurposing” research approach to identify treatments for rare diseases.

Medable won the Most Valuable Clinical Technology Award and the Health Entrepreneur Award at the Reuters Pharma Awards USA 2022. This double recognition underscores Medable’s leadership in applying digital methodology to clinical research at scale.

Medable was named a Leader in the “Decentralized Clinical Trial Products PEAK Matrix® Assessment 2022” by Everest Group for the second consecutive year. The report evaluates decentralized clinical trial (DCT) products from 24 companies. Medable rated highest in the Leaders quadrant with top scores for vision, capability and market impact.

‍

Medable, the industry-leading technology platform for patient-centered clinical trials, today announced the availability of its Total Consent offering, a fully enabled SaaS electronic consent management solution compatible with every clinical trial, in more than 120 locales around the globe. With this launch, Medable’s Total Consent offering is at the forefront of optimizing the informed consent process for potential trial participants by improving patient accessibility, knowledge, and experience, in line with the release of the proposed FDA rule, Protection of Human Subjects and Institutional Review Boards.